Rhodes Pharmaceuticals announced today that the FDA has granted approval for ANDA 207808, which, pending market entry, will allow the company to capitalize on generic demand for this product. This regulatory clearance strengthens the company’s supply chain and diversifies its product portfolio, positioning it to capture additional market share within the specific pharmaceutical segment.